Unknown

Dataset Information

CD200 is induced by ERK and is a potential therapeutic target in melanoma.


ABSTRACT: Immune-mediated antitumor responses occur in patients with metastatic melanoma (MM), and therapies designed to augment such responses are clinically beneficial. Despite the immunogenicity of melanoma, immunomodulatory therapies fail in the majority of patients with MM. An inability of DCs to sufficiently activate effector cells may, in part, underlie this failure of the antitumor response seen in most patients. In this work, we show that mutation of N-RAS or B-RAF, signature genetic lesions present in most MMs, potently induced the expression of cell-surface CD200, a repressor of DC function. Employing 2 independent, genome-wide microarray analyses, we identified CD200 as a highly dynamic, downstream target of RAS/RAF/MEK/ERK activation in melanoma. CD200 protein was similarly overexpresse

SUBMITTER: Petermann KB 

PROVIDER: S-EPMC2075477 | biostudies-literature | 2007 Dec

REPOSITORIES: biostudies-literature